Table 3.
Study | Sequence generation | Concealment | Blinded Outcome Assessment | Intention-to- Treat Analysis | For-Profit Bias |
---|---|---|---|---|---|
Placebo-controlled trials | |||||
McIntyre et al., 2014 | Low | Low | Low | Low | High |
Katona et al., 2012 | Low | Low | Low | Low | High |
Mahableshwarkar et al., 2015 | Low | Low | Low | High | High |
Raskin et al., 2007 | Low | Low | Low | Low | High |
Robinson et al., 2014 | Low | Low | Low | Low | High |
Culang et al., 2009 | Low | Low | Low | Low | High |
Ferguson et al., 2003 | Low | Low | Low | Low | HIgh |
Georgotas et al., 1989 | Low | Low | Low | High | Low |
Hoffman et al., 2008 | Low | Low | Low | Low | Low |
Comparative Trials | |||||
Bondareff et al., 2000 | Low | Low | Low | High | High |
Culang-Reinlieb et al., 2012 | Low | Low | Low | High | Low |
Levkovitz et al., 2002 | Low | Low | High | Low | Low |
Trick et al., 2004 | Low | Low | Low | High | High |
Newhouse et al., 2000 | Low | Low | Low | High | High |
Finkel et al., 1999 | Low | Low | Low | High | High |
Soczynska et al., 2014 | Low | Low | Low | Low | High |
Gorlyn et al., 2015 | Low | Low | Low | Low | Low |